Dorsey Wright & Associates Invests $1.03 Million in Illumina, Inc. $ILMN

Dorsey Wright & Associates bought a new stake in Illumina, Inc. (NASDAQ:ILMN) during the first quarter, Holdings Channel reports. The institutional investor bought 8,337 shares of the life sciences company’s stock, valued at approximately $1,028,000.

Several other hedge funds also recently modified their holdings of ILMN. Capital World Investors grew its holdings in Illumina by 0.6% during the fourth quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock worth $2,636,483,000 after buying an additional 124,323 shares in the last quarter. State Street Corp raised its position in Illumina by 3.2% in the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock valued at $811,895,000 after buying an additional 190,324 shares during the last quarter. AQR Capital Management LLC lifted its stake in Illumina by 30.3% during the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after acquiring an additional 1,028,099 shares in the last quarter. Geode Capital Management LLC lifted its stake in Illumina by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock valued at $375,260,000 after acquiring an additional 130,139 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in Illumina by 97.0% during the 4th quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after acquiring an additional 1,352,731 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Activity at Illumina

In other Illumina news, Director Keith A. Meister sold 235,000 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $163.63, for a total value of $38,453,050.00. Following the transaction, the director directly owned 2,830,452 shares in the company, valued at $463,146,860.76. The trade was a 7.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Scott M. Davies sold 615 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total transaction of $110,700.00. Following the transaction, the insider directly owned 20,953 shares of the company’s stock, valued at $3,771,540. This represents a 2.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,003,769 shares of company stock worth $155,710,908. 2.90% of the stock is currently owned by corporate insiders.

Illumina Stock Down 1.9%

Shares of NASDAQ:ILMN opened at $186.65 on Friday. The company has a market capitalization of $28.24 billion, a PE ratio of 33.94, a price-to-earnings-growth ratio of 3.49 and a beta of 1.47. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The business has a fifty day moving average price of $166.44 and a two-hundred day moving average price of $143.34. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $196.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Analysts forecast that Illumina, Inc. will post 5.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several recent analyst reports. Leerink Partners upped their target price on shares of Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research note on Friday. JPMorgan Chase & Co. raised shares of Illumina from a “neutral” rating to an “overweight” rating and raised their price target for the company from $125.00 to $185.00 in a research report on Wednesday, June 10th. Sanford C. Bernstein assumed coverage on shares of Illumina in a report on Friday, June 26th. They set a “market perform” rating and a $185.00 price target on the stock. Piper Sandler upped their price objective on shares of Illumina from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 1st. Finally, Canaccord Genuity Group increased their price objective on shares of Illumina from $140.00 to $190.00 and gave the company a “hold” rating in a research note on Tuesday, July 14th. Nine investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $156.88.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.